Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study
LANE J., Weaves J., Kostka K., Duarte-Salles T., Abrahao MT., Alghoul H., Alser O., alshammari T., Biedermann P., Burn E., Casajust P., Conover M., Culhane A., Daydov A., DuVall S., Dymshyts D., Fernandez-Bertolin S., Fister K., Hardin J., Hester L., Hripcsak G., KENT S., Khosla S., KOLOVOS S., Lambert C., van der Lei J., Londhe A., Lynch K., Makadia R., Margulis A., Matheny M., Mehta P., Morales D., Morgan-Stewart H., Mossveld M., NEWBY D., Nyberg F., Ostropolets A., Park RW., Prats Uribe A., Gowtham R., Reich C., Reps J., Rijnbeek P., Sathappan SMK., Schuemie M., seager S., Sena A., Shoaibi A., Spotnitz M., Suchard M., Swerdel J., Torre C., Vizcaya D., Wen H., De Wilde M., You SC., Zhang L., Zhuk O., Ryan P., PRIETO ALHAMBRA D.
Background: Hydroxychloroquine has recently received Emergency Use Authorization by the FDA and is currently prescribed in combination with azithromycin for COVID-19 pneumonia. We studied the safety of hydroxychloroquine, alone and in combination with azithromycin. Methods: New user cohort studies were conducted including 16 severe adverse events (SAEs). Rheumatoid arthritis patients aged 18+ and initiating hydroxychloroquine were compared to those initiating sulfasalazine and followed up over 30 days. Self-controlled case series (SCCS) were conducted to further establish safety in wider populations. Separately, SAEs associated with hydroxychloroquine-azithromycin (compared to hydroxychloroquine-amoxicillin) were studied. Data comprised 14 sources of claims data or electronic medical records from Germany, Japan, Netherlands, Spain, UK, and USA. Propensity score stratification and calibration using negative control outcomes were used to address confounding. Cox models were fitted to estimate calibrated hazard ratios (CalHRs) according to drug use. Estimates were pooled where I2<40%. Results: Overall, 956,374 and 310,350 users of hydroxychloroquine and sulfasalazine, and 323,122 and 351,956 users of hydroxychloroquine-azithromycin and hydroxychloroquine-amoxicillin were included. No excess risk of SAEs was identified when 30-day hydroxychloroquine and sulfasalazine use were compared. SCCS confirmed these findings. However, when azithromycin was added to hydroxychloroquine, we observed an increased risk of 30-day cardiovascular mortality (CalHR2.19 [1.22-3.94]), chest pain/angina (CalHR 1.15 [95% CI 1.05-1.26]), and heart failure (CalHR 1.22 [95% CI 1.02-1.45]) Conclusions: Short-term hydroxychloroquine treatment is safe, but addition of azithromycin may induce heart failure and cardiovascular mortality, potentially due to synergistic effects on QT length. We call for caution if such combination is to be used in the management of Covid-19.